Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | June 21, 2017 | June 23, 2017 |
| Better Therapeutics, Inc.BTTX · Entity 94385 | Director · Chief Executive Officer | December 18, 2023 | December 20, 2023 |
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Director | May 05, 2020 | May 28, 2020 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | Principal Fin'l & Accounting | July 07, 2021 | July 09, 2021 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date June 21, 2017 · Filed June 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2027-06-21 | Direct | 22,000 |
Reported balance
After 2017-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-21 · Grant · Acquired 22,000 · Balance 22,000 F1: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately exercisable.
Better Therapeutics, Inc.
Report date December 18, 2023 · Filed December 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 526,516 |
Reported balance
After 2023-12-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-18 · Grant · Acquired 62,500 · Balance 526,516 F1: The Reporting person was awarded 62,500 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024. F2: Includes 34,587 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting person was awarded 62,500 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024.
F2: Includes 34,587 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2023.
CHINOOK THERAPEUTICS, INC.
Report date May 05, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2030-05-04 | Direct | 30,000 |
Reported balance
After 2020-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant.
Myovant Sciences Ltd.
Report date July 07, 2021 · Filed July 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 212,296 |
Reported balance
After 2021-07-07 transaction · row 1
1 source rowRow 1 · 2021-07-07 · Sale · Disposed 3,232 · Balance 212,296 F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2: The shares were sold at prices ranging from $21.75 to $21.83. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
F2: The shares were sold at prices ranging from $21.75 to $21.83. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Phathom Pharmaceuticals, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 91,622 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 24,122 · Balance 91,622 F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cidara Therapeutics, Inc.
Report date January 07, 2026 · Filed January 08, 2026
Section 16 reporting ended · disclosed 2026-01-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-01-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-07 · Disposition to issuer · Disposed 7,526 · Balance 43,125 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes. F4: Includes 89 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025. Row 2 · 2026-01-07 · Disposition to issuer · Disposed 43,125 · Balance 0 F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.50 · Expires 2035-02-23 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Disposition to issuer · Disposed 115,000 · Balance 0 F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2]
F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]
F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes.
F4: Includes 89 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025.
F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share.
F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2020 Filed Nov 17, 2020 23:50 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 750 | $5.11 | $3,832.50 |
DisclosureSEC source: 0001209191-20-058894 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-050887 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,394 Underlying: Common Shares · 750 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 750 | $21.73 | $16,297.50 |
DisclosureSEC source: 0001209191-20-050887 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $21.46 to $21.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 750 | $5.11 | $3,832.50 |
DisclosureSEC source: 0001209191-20-050887 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:37 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,150 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-048927 · doc4.xml · derivative · entry 6 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,144 Underlying: Common Shares · 21,150 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:37 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 21,150 | $20.01 | $423,274.95 |
DisclosureSEC source: 0001209191-20-048927 · doc4.xml · nonDerivative · entry 4 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F3 · price: The shares were sold at prices ranging from $20.00 to $20.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:37 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 21,150 | $5.11 | $108,076.50 |
DisclosureSEC source: 0001209191-20-048927 · doc4.xml · nonDerivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 20:37 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,650 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-048927 · doc4.xml · derivative · entry 5 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,294 Underlying: Common Shares · 3,650 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 20:37 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 3,650 | $20.04 | $73,146.00 |
DisclosureSEC source: 0001209191-20-048927 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $20.00 to $20.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 20:37 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 3,650 | $5.11 | $18,651.50 |
DisclosureSEC source: 0001209191-20-048927 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 21:07 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-047968 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,944 Underlying: Common Shares · 700 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 21:07 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 700 | $20.00 | $14,000.00 |
DisclosureSEC source: 0001209191-20-047968 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 21:07 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 700 | $5.11 | $3,577.00 |
DisclosureSEC source: 0001209191-20-047968 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 28, 2020 20:00 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011289 · doc1.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-04 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:10 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 183,991 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0001209191-20-023794 · doc4.xml · derivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,991 Underlying: Common Shares · 183,991 shares Expires 2030-04-02 F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:10 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 120,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023794 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 00:13 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 19,701 | $15.55 | $306,350.55 |
DisclosureSEC source: 0001209191-19-062187 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,324 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 132,270 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047542 · doc4.xml · derivative · entry 7 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,270 Underlying: Common Shares · 132,270 shares Expires 2029-04-04 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F5 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 132,270 | $0.00 Strike: $24.44 | $0.00 |
DisclosureSEC source: 0001209191-19-047542 · doc4.xml · derivative · entry 6 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 132,270 shares Expires 2029-04-04 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F5 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 114,690 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047542 · doc4.xml · derivative · entry 5 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,690 Underlying: Common Shares · 114,690 shares Expires 2028-04-15 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F4 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 114,690 | $0.00 Strike: $21.87 | $0.00 |
DisclosureSEC source: 0001209191-19-047542 · doc4.xml · derivative · entry 4 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 114,690 shares Expires 2028-04-15 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F4 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047542 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2027-05-14 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F3 · derivative.exercise_date: 1/4 of the shares underlying the option vested on May 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001209191-19-047542 · doc4.xml · derivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 200,000 shares Expires 2027-05-14 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F3 · derivative.exercise_date: 1/4 of the shares underlying the option vested on May 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 55,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-047542 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,025 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. The RSUs shall vest as follows: (i) 1/3 of the total shares subject to the RSUs shall vest at the later occurrence of (a) the achievement of certain milestones and (b) the first anniversary of the grant date; and (ii) 2/3 of the total shares subject to the RSUs shall vest as follows: 1/8 vesting on the first anniversary of the grant date and 7/8 vesting in seven even installments each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Shares | 8,000 | $9.10 | $72,800.00 |
DisclosureSEC source: 0001209191-19-036115 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| May 14, 2019 Filed May 15, 2019 19:05 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001567619-19-011356 · doc1.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-13 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of May 14, 2019, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| April 18, 2019 Filed Apr 19, 2019 16:15 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantInitial Option Grant · Derivative | 60,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001567619-19-008985 · doc1.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-04-17 F1 · derivative.exercise_date: The shares subject to the initial option grant vest 1/3 after the first year, the remaining shares will vest quarterly in years two and three following the grant date of April 18, 2019. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:14 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 132,270 | $0.00 Strike: $24.44 | $0.00 |
DisclosureSEC source: 0001209191-19-024132 · doc4.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,270 Underlying: Common Stock · 132,270 shares Expires 2029-05-04 F1 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 22:40 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 114,690 | $0.00 Strike: $21.87 | $0.00 |
DisclosureSEC source: 0001209191-18-025453 · doc4.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,690 Underlying: Common Shares · 114,690 shares Expires 2028-04-15 F1 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 16, 2019, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter measured from April 16, 2019, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:01 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001209191-17-041627 · doc4.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:09 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001209191-17-033224 · doc4.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2027-05-14 F1 · derivative.exercise_date: 25% of the shares underlying the option vest and become exercisable on May 15, 2018; the balance of the shares vest and become exercisable in a series of twelve (12) successive equal quarterly installments measured from May 15, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.